CD8A and neoplasm: As expected, expansion was greatest in CLL patients with the highest peak (over 95% of CD8+ cells) in the patient with the highest proportion of circulating tumor lymphocytes perhaps due to increased antigen exposure, whereas peak levels in patients with solid tumors were much lower, and 4 out of 18 patients had peak CAR-T levels < 3% of circulating CD8+ cells.